查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1945801

肝素誘發血小板減少性疾病市場－全球產業規模、佔有率、趨勢、機會及預測（依治療藥物、通路、地區及競爭格局分類，2021-2031年）

Heparin-Induced Thrombocytopenia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Drug, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肝素誘發血小板減少性疾病(HIT) 市場預計將從 2025 年的 98.7 億美元成長到 2031 年的 133.6 億美元，複合年成長率為 5.18%。

肝素誘發的血小板減少性疾病(HIT) 是嚴重的抗體介導的肝素暴露反應，其特徵是血小板計數迅速下降和矛盾的血栓形成傾向。市場成長的主要促進因素是需要抗凝血治療的複雜心血管和整形外科手術日益增多，以及臨床治療偏好轉向非肝素療法。國際血栓與止血學會 (ISTH) 的一份報告也印證了這種不斷變化的治療標準。報告指出，到 2024 年，74.5% 的受訪專家支持使用Rivaroxaban伐沙班治療 HIT，即使在血小板恢復之前，這將推動直介面服抗凝血劑 (DOAC) 的應用。

市場概覽
預測期 2027-2031
市場規模：2025年 98.7億美元
市場規模：2031年 133.6億美元
複合年成長率：2026-2031年 5.18%
成長最快的細分市場 阿加曲班
最大的市場 北美洲

然而，該市場在診斷準確性方面面臨許多障礙。廣泛使用的免疫檢測方法經常出現假陽性結果，這不僅使臨床決策複雜化，還常常導致不必要的昂貴替代療法的使用。這種診斷不確定性降低了患者照護效率，並給醫療保健系統帶來了沉重的經濟負擔，從而限制了市場在成本敏感地區的擴張。

市場促進因素

全球外科手術量的不斷成長是市場發展的根本驅動力，因為肝素仍然是心肺體外迴圈和大型整形外科手術的標準抗凝血劑。隨著全球人口老化，對更複雜手術的需求增加，導致未分級肝素的累積暴露增加，以及發生免疫介導不良反應的患者絕對數量增加。 2023年12月《胸腔外科年鑑》簡報的數據顯示，高所得國家平均每年每10萬人進行123.2例心臟外科手術，凸顯了肝素使用的巨大規模。這種廣泛的暴露與疾病負擔相關，美國血液學會估計，到2024年，肝素誘導的血栓症（HIT）將影響每年約1500名住院患者中的1人，這將持續推動對診斷和治療解決方案的需求。

同時，非肝素抗凝血藥物的日益普及正在改變市場格局。隨著臨床醫生優先選擇安全性更高的藥物用於高風險患者，醫療專業人員正逐步轉向使用直接凝血酶抑制劑進行易感人群的根治性治療和預防，從而減少對傳統肝素通訊協定的依賴。這一轉變得到了可靠的臨床證據支持。例如，2024年10月出版的《美國心臟學會雜誌》報道，在一項針對接受經皮皮冠狀動脈介入治療（PCI）患者的大型Meta分析中，比伐盧定將30天全因死亡率降低至2.5%，而肝素組為2.9%。諸如此類的研究結果正在加速非肝素類藥物被納入醫院處方集，從而推動了替代抗凝血藥物的收入成長。

市場挑戰

全球肝素誘發血小板減少性疾病(HIT) 市場擴張的主要障礙在於診斷準確性方面持續存在的挑戰，尤其是標準篩檢試驗中較高的假陽性率。儘管目前的免疫測定法靈敏度較高，但其特異性往往不足以區分致病性抗體和非致病性突變。這種診斷上的不確定性迫使醫療服務提供者在沒有臨床症狀的情況下，也不得不預防性地停用肝素，轉而使用昂貴的替代抗凝血劑。根據美國血液學會 (ASH) 2024 年的報告，臨床數據顯示，廣泛使用的免疫檢測在高達 50% 的心血管手術患者中出現假陽性結果，導致嚴重的診斷混亂。

這種不確定性導致醫療成本上漲和資源配置效率低下，直接影響市場成長。使用昂貴的非肝素療法治療假陽性病例會對醫院預算造成沉重的經濟負擔，尤其是在對成本敏感的地區。因此，醫療機構管理者在採購高成本的替代療法時往往會更加謹慎，這限制了銷售量。由於缺乏快速且準確的診斷確認而導致的這種財務猶豫，阻礙了先進治療方法的廣泛商業性應用，並限制了整體市場收入潛力。

市場趨勢

在開發平臺中，一項重要的進展是新型12-脂氧合酶（12-LOX）抑制劑的研發。這類抑制劑針對上游酶促通路，在不損害止血功能的前提下抑制血小板活化。這種作用機制代表著對傳統凝血酶抑制策略的策略性轉變，旨在最大程度地降低複雜病例的出血風險。例如，2024年8月，Veralox Therapeutics公司宣布，其主要候選藥物VLX-1005獲得了歐洲藥品管理局（EMA）授予的孤兒藥資格認定，用於治療血小板活化因子4（PAF4）相關疾病。這項監管核准表明，業界正日益關注開發具有緩解疾病特性的First-in-Class小分子藥物，這些藥物比目前用於高風險患者群體的抗凝血劑更安全。

同時，市場正朝著快速、自動化的診斷測試方向發展，特別是化學冷光免疫檢測，以克服人工檢測的限制。這些系統能夠在重症監護環境中快速排除診斷，從而解決假陽性結果帶來的效率低下問題。 2024年6月，國際血栓與止血學會報告了一種新的化學冷光免疫檢測，該方法在疑似患者中展現出77.4%的特異性，優於特異性在62.4%至74.2%之間的同類抗體檢測法。這項進步使臨床醫生能夠透過快速排除疾病並避免不必要的昂貴治療，從而最佳化抗凝血治療的合理應用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球肝素誘發血小板減少性疾病市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依治療類型（阿加曲班、來匹盧定、達那帕羅鈉、其他）
    • 按分銷管道（醫院/診所、門診護理中心、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美肝素誘發血小板減少性疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲肝素誘發血小板減少性疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區肝素誘發血小板減少性疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲肝素誘發血小板減少性疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美肝素誘發血小板減少性疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球肝素誘發血小板減少性疾病市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Mitsubishi Tanabe Pharma
  • Auromedics Pharma Llc
  • Fresenius Kabi USA
  • Pfizer Inc
  • DAIICHI SANKYO COMPANY, LIMITED
  • Caplin Steriles Ltd
  • Hikma Pharmaceuticals PLC
  • NOVARTIS AG
  • Endo International plc
  • Gland Pharma Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17290

The Global Heparin-Induced Thrombocytopenia Market is projected to expand from USD 9.87 Billion in 2025 to USD 13.36 Billion by 2031, registering a compound annual growth rate of 5.18%. Heparin-Induced Thrombocytopenia (HIT) is defined as a serious, antibody-mediated reaction to heparin exposure, marked by a rapid decrease in platelet count and a contradictory prothrombotic condition. Market growth is primarily underpinned by the increasing frequency of complex cardiovascular and orthopedic surgeries requiring anticoagulation, alongside a shift in clinical preference toward non-heparin therapies. This evolution in therapeutic standards is highlighted by the International Society on Thrombosis and Haemostasis, which reported in 2024 that 74.5% of surveyed experts supported using rivaroxaban for HIT management even before platelet recovery, a factor that fuels the adoption of direct oral anticoagulants.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 9.87 Billion
Market Size 2031USD 13.36 Billion
CAGR 2026-20315.18%
Fastest Growing SegmentArgatroban
Largest MarketNorth America

Nevertheless, the market encounters substantial obstacles related to diagnostic precision. The frequent occurrence of false-positive results in widely utilized immunological assays complicates clinical judgment and often results in the unnecessary application of expensive alternative treatments. This diagnostic uncertainty creates inefficiencies in patient care and places significant financial strain on healthcare systems, thereby limiting broader market expansion in regions that are sensitive to costs.

Market Driver

The rising global volume of surgical procedures serves as a fundamental catalyst for the market, given that heparin remains the standard anticoagulant for cardiopulmonary bypass and major orthopedic interventions. As the global population ages and requires more frequent complex surgeries, the cumulative exposure to unfractionated heparin increases, leading to a rise in the absolute number of patients developing immune-mediated adverse reactions. Data from the Annals of Thoracic Surgery Short Reports in December 2023 indicates that high-income nations maintained an average total cardiac surgical volume of 123.2 procedures per 100,000 people annually, highlighting the massive scale of heparin utilization. This widespread exposure correlates with disease burden, as the American Society of Hematology estimated in 2024 that HIT affects approximately 1 in 1,500 hospitalizations annually, driving sustained demand for diagnostic and therapeutic solutions.

Concurrently, the increasing adoption of non-heparin anticoagulant therapies is reshaping the market landscape as clinicians prioritize agents with superior safety profiles for high-risk patients. Medical professionals are shifting toward direct thrombin inhibitors for both confirmed treatment and prevention in susceptible cohorts, reducing reliance on traditional heparin protocols. This transition is supported by robust clinical evidence; for instance, the Journal of the American College of Cardiology reported in October 2024 that a large-scale meta-analysis of patients undergoing primary percutaneous coronary intervention showed bivalirudin reduced 30-day all-cause mortality to 2.5%, compared to 2.9% for heparin. Such findings accelerate the integration of non-heparin pharmacotherapies into hospital formularies and drive revenue growth for alternative anticoagulants.

Market Challenge

The primary impediment hindering the expansion of the Global Heparin-Induced Thrombocytopenia Market is the persistent challenge regarding diagnostic accuracy, particularly the high rate of false-positive results associated with standard screening tests. Although current immunological assays are sensitive, they frequently lack the necessary specificity to differentiate between pathogenic antibodies and non-pathogenic variations. This diagnostic ambiguity compels healthcare providers to discontinue heparin and initiate expensive alternative anticoagulants as a precaution, even when the clinical condition is not present. According to the American Society of Hematology in 2024, clinical data indicated that widely utilized immunoassays yield false-positive results in up to 50 percent of cardiac surgery patients, leading to significant diagnostic confusion.

This uncertainty directly impacts market growth by inflating healthcare costs and creating inefficiencies in resource allocation. The financial burden incurred from treating false-positive cases with premium non-heparin therapies strains hospital budgets, particularly in cost-sensitive regions. Consequently, healthcare administrators often exercise greater fiscal caution in procuring high-cost alternative drugs, which limits sales volumes. This economic hesitation, driven by the inability to rapidly and accurately confirm the diagnosis, restricts the broader commercial adoption of advanced therapeutics and suppresses overall market revenue potential.

Market Trends

A significant trend in the development pipeline is the advancement of novel 12-lipoxygenase (12-LOX) inhibitors, which target upstream enzymatic pathways to reduce platelet activation without compromising hemostasis. This mechanism represents a strategic departure from traditional thrombin inhibition, aiming to minimize bleeding risks in complex cases. For example, Veralox Therapeutics announced in August 2024 that the European Medicines Agency granted Orphan Drug Designation to their lead candidate, VLX-1005, for treating platelet-activating anti-Platelet Factor 4 disorders. This regulatory endorsement highlights the growing industry commitment to developing first-in-class small molecule drugs that provide safer, disease-modifying alternatives to current anticoagulants for high-risk patient populations.

Simultaneously, the market is observing a transition toward rapid automated diagnostic assays, particularly chemiluminescent immunoassays, to overcome the limitations of manual testing. These systems facilitate quicker exclusion of diagnoses in critical care settings, addressing inefficiencies caused by false-positive results. In June 2024, the International Society on Thrombosis and Haemostasis highlighted a new chemiluminescent immunoassay that demonstrated a specificity of 77.4% in suspected patients, outperforming comparative antibody assays which ranged between 62.4% and 74.2%. This advancement enables clinicians to optimize anticoagulant stewardship by rapidly ruling out the condition, preventing the unnecessary utilization of expensive therapies.

Key Market Players

  • Mitsubishi Tanabe Pharma
  • Auromedics Pharma Llc
  • Fresenius Kabi USA
  • Pfizer Inc
  • DAIICHI SANKYO COMPANY, LIMITED
  • Caplin Steriles Ltd
  • Hikma Pharmaceuticals PLC
  • NOVARTIS AG
  • Endo International plc
  • Gland Pharma Ltd

Report Scope

In this report, the Global Heparin-Induced Thrombocytopenia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Heparin-Induced Thrombocytopenia Market, By Treatment Drug

  • Argatroban
  • Lepirudin
  • Danaparoid
  • Others

Heparin-Induced Thrombocytopenia Market, By Distribution Channel

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Heparin-Induced Thrombocytopenia Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Heparin-Induced Thrombocytopenia Market.

Available Customizations:

Global Heparin-Induced Thrombocytopenia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Heparin-Induced Thrombocytopenia Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Drug (Argatroban, Lepirudin, Danaparoid, Others)
    • 5.2.2. By Distribution Channel (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Heparin-Induced Thrombocytopenia Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Drug
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Heparin-Induced Thrombocytopenia Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Drug
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Heparin-Induced Thrombocytopenia Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Drug
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Heparin-Induced Thrombocytopenia Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Drug
        • 6.3.3.2.2. By Distribution Channel

7. Europe Heparin-Induced Thrombocytopenia Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Drug
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Heparin-Induced Thrombocytopenia Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Drug
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Heparin-Induced Thrombocytopenia Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Drug
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Heparin-Induced Thrombocytopenia Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Drug
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Heparin-Induced Thrombocytopenia Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Drug
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Heparin-Induced Thrombocytopenia Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Drug
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Heparin-Induced Thrombocytopenia Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Drug
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Heparin-Induced Thrombocytopenia Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Drug
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Heparin-Induced Thrombocytopenia Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Drug
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Heparin-Induced Thrombocytopenia Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Drug
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Heparin-Induced Thrombocytopenia Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Drug
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Heparin-Induced Thrombocytopenia Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Drug
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Heparin-Induced Thrombocytopenia Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Drug
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Heparin-Induced Thrombocytopenia Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Drug
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Heparin-Induced Thrombocytopenia Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Drug
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Heparin-Induced Thrombocytopenia Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Drug
        • 9.3.3.2.2. By Distribution Channel

10. South America Heparin-Induced Thrombocytopenia Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Drug
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Heparin-Induced Thrombocytopenia Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Drug
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Heparin-Induced Thrombocytopenia Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Drug
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Heparin-Induced Thrombocytopenia Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Drug
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Heparin-Induced Thrombocytopenia Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Mitsubishi Tanabe Pharma
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Auromedics Pharma Llc
  • 15.3. Fresenius Kabi USA
  • 15.4. Pfizer Inc
  • 15.5. DAIICHI SANKYO COMPANY, LIMITED
  • 15.6. Caplin Steriles Ltd
  • 15.7. Hikma Pharmaceuticals PLC
  • 15.8. NOVARTIS AG
  • 15.9. Endo International plc
  • 15.10. Gland Pharma Ltd

16. Strategic Recommendations

17. About Us & Disclaimer